Tri-sprintec and Hair loss - a phase IV clinical study of FDA data


Hair loss is found among people who take Tri-sprintec, especially for people who are female, 20-29 old, have been taking the drug for 6 - 12 months.

The phase IV clinical study analyzes which people take Tri-sprintec and have Hair loss. It is created by eHealthMe based on reports of 924 people who have side effects when taking Tri-sprintec from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 04, 2022

924 people reported to have side effects when taking Tri-sprintec.
Among them, 18 people (1.95%) have Hair loss.

What is Tri-sprintec?

Tri-sprintec has active ingredients of ethinyl estradiol; norgestimate. It is often used in birth control. eHealthMe is studying from 1,298 Tri-sprintec users for its effectiveness, alternative drugs and more.

What is Hair loss?

Hair loss is found to be associated with 3,695 drugs and 3,258 conditions by eHealthMe.

Number of Tri-sprintec and Hair loss reports submitted per year:

Could Tri-sprintec cause Hair loss?

Time on Tri-sprintec when people have Hair loss *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 33.33 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 33.33 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hair loss when taking Tri-sprintec *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Hair loss when taking Tri-sprintec *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 7.69 %
  • 20-29: 38.46 %
  • 30-39: 15.38 %
  • 40-49: 23.08 %
  • 50-59: 15.38 %
  • 60+: 0.0 %

Common drugs people take besides Tri-sprintec *:

  1. Escitalopram: 2 people, 11.11%
  2. Promethazine: 2 people, 11.11%
  3. Aleve: 2 people, 11.11%
  4. Aubagio: 2 people, 11.11%
  5. Biotin: 2 people, 11.11%
  6. Neosar: 2 people, 11.11%
  7. Humira: 2 people, 11.11%
  8. Iron Dextran: 1 person, 5.56%
  9. Intron A: 1 person, 5.56%
  10. Ibuprofen: 1 person, 5.56%

Common side effects people have besides Hair loss *:

  1. Headache (pain in head): 4 people, 22.22%
  2. Nausea (feeling of having an urge to vomit): 3 people, 16.67%
  3. Vitamin D Decreased: 2 people, 11.11%
  4. Influenza Like Illness: 2 people, 11.11%
  5. Joint Pain: 2 people, 11.11%
  6. Fever: 2 people, 11.11%
  7. Psoriasis (immune-mediated disease that affects the skin): 2 people, 11.11%
  8. Fatigue (feeling of tiredness): 2 people, 11.11%
  9. Excessive Or Unwanted Hair In Women: 1 person, 5.56%
  10. Hair Disorder: 1 person, 5.56%

Common conditions people have *:

  1. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 27.78%
  2. Breast Cancer Female: 2 people, 11.11%
  3. Skin Disorder (skin disease): 1 person, 5.56%
  4. Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 1 person, 5.56%
  5. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 5.56%
  6. Psoriasis (immune-mediated disease that affects the skin): 1 person, 5.56%
  7. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 5.56%
  8. Nail Disorder (disease of nail): 1 person, 5.56%
  9. Malignant Melanoma (skin cancer rises from melancytes): 1 person, 5.56%
  10. Immunodeficiency Disorders: 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Tri-sprintec and have Hair loss?

Check whether Hair loss is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Hair loss and when was it recovered:

Expand to all the drugs that have ingredients of ethinyl estradiol; norgestimate:

Alternative drugs to, pros and cons of Tri-sprintec:

Hair loss treatments and more:

COVID vaccines that are related to Hair loss:

Common drugs associated with Hair loss:

All the drugs that are associated with Hair loss:

Common conditions associated with Hair loss:

All the conditions that are associated with Hair loss:

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; norgestimate (the active ingredients of Tri-sprintec) and Tri-sprintec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: